UniProtKB/Swiss-Prot O95999 : Variant p.Arg64Lys
B-cell lymphoma/leukemia 10
Gene: BCL10
Feedback ?
Variant information
Variant position:
64
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
US
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Arginine (R) to Lysine (K) at position 64 (R64K, p.Arg64Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Similar physico-chemical property. Both residues are large size and basic.
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
Found in a MALT lymphoma sample; uncertain significance.
Any additional useful information about the variant.
Sequence information
Variant position:
64
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
233
The length of the canonical sequence.
Location on the sequence:
KKILSREDTEEISCRTSSRK
R AGKLLDYLQENPKGLDTLVE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KKILSREDTEEISCRTSSRKR AGKLLDYLQENPKGLDTLVE
Mouse KKILSREDTEEISCRTSSRKR AGKLLDYLQENPRGLDTLVE
Rat KKILSREDTEEISCRTSSRKR AGKLLDYLQENPKGLDTLVE
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 233
B-cell lymphoma/leukemia 10
Domain
13 – 101
CARD
Cross
63 – 63
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Mutagenesis
46 – 46
I -> A. Abolishes cell death-inducing capability.
Mutagenesis
47 – 47
L -> A. Abolishes cell death-inducing capability.
Mutagenesis
50 – 50
E -> R. Abolished homomultimerization and formation of a CBM complex, abolished ability to activate NF-kappa-B.
Mutagenesis
53 – 53
E -> A. Abolishes cell death-inducing capability.
Mutagenesis
53 – 53
E -> R. Abolished homomultimerization and formation of a CBM complex, abolished ability to activate NF-kappa-B.
Mutagenesis
55 – 55
I -> A. Abolishes cell death-inducing capability.
Mutagenesis
63 – 67
KRAGK -> RRAGR. Decreased ubiquitination and ability to bind NEMO; when associated with R-31.
Mutagenesis
63 – 63
K -> R. Decreased ubiquitination and ability to bind NEMO, impaired ability to activate NF-kappa-B; when associated with R-31. Decreased linear ubiquitination and impaired ability to activate NF-kappa-B; when associated with R-17 and R-31.
Mutagenesis
78 – 78
G -> R. Abolishes NF-kappa-B activation.
Helix
61 – 72
Literature citations
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32).
Zhang Q.; Siebert R.; Yan M.; Hinzmann B.; Cui X.; Xue L.; Rakestraw K.M.; Naeve C.W.; Beckmann G.; Weisenburger D.D.; Sanger W.G.; Nowotny H.; Vesely M.; Callet-Bauchu E.; Salles G.; Dixit V.M.; Rosenthal A.; Schlegelberger B.; Morris S.W.;
Nat. Genet. 22:63-68(1999)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]; VARIANTS SER-5; GLU-16; GLU-31; ARG-57; LYS-64; GLU-101; PRO-134; ALA-168; SER-174; GLU-213 AND ILE-230;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.